Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL® “These new findings are consistent with my ...
MediWound Ltd. announced the publication of a peer-reviewed post hoc analysis in the journal Wounds, based on data from its Phase II ChronEx clinical trial for patients with venous leg ulcers (VLUs).
September 24, 2012 — The European Medicines Agency (EMA) has recommended approval of the first enzyme-based debriding agent (NexoBrid, MediWound Ltd) to remove eschar from second- and third-degree ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback